Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Neuroscience ; 169(1): 402-14, 2010 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-20423721

RESUMO

Hyperglycemia is one of the major factors for hemorrhagic transformation after ischemic stroke. In this study, we tested the effect of hydrogen gas on hemorrhagic transformation in a rat focal cerebral ischemia model. Sprague-Dawley rats (n=72) were divided into the following groups: sham; sham treated with hydrogen gas (H(2)); Middle Cerebral Artery Occlusion (MCAO); and MCAO treated with H(2) (MCAO+H(2)). All rats received an injection of 50% dextrose (6 ml/kg i.p.) and underwent MCAO 15 min later. Following a 90 min ischemic period, hydrogen was inhaled for 2 h during reperfusion. We measured the level of blood glucose at 0 h, 0.5 h, 4 h, and 6 h after dextrose injection. Infarct and hemorrhagic volumes, neurologic score, oxidative stress (evaluated by measuring the level of 8 Hydroxyguanosine (8OHG), 4-Hydroxy-2-Nonenal (HNE) and nitrotyrosine), and matrix metalloproteinase (MMP)-2/MMP-9 activity were measured at 24 h after ischemia. We found that hydrogen inhalation for 2 h reduced infarct and hemorrhagic volumes and improved neurological functions. This effect of hydrogen was accompanied by a reduction of the expression of 8OHG, HNE, and nitrotyrosine and the activity of MMP-9. Furthermore, a reduction of the blood glucose level from 500+/-32.51 to 366+/-68.22 mg/dl at 4 h after dextrose injection was observed in hydrogen treated animals. However, the treatment had no significant effect on the expression of ZO-1, occludin, collagen IV or aquaporin4 (AQP4). In conclusion, hydrogen gas reduced brain infarction, hemorrhagic transformation, and improved neurological function in rats. The potential mechanisms of decreased oxidative stress and glucose levels after hydrogen treatment warrant further investigation.


Assuntos
Antioxidantes/uso terapêutico , Hemorragia Cerebral/prevenção & controle , Hidrogênio/uso terapêutico , Hiperglicemia/complicações , Infarto da Artéria Cerebral Média/tratamento farmacológico , Fármacos Neuroprotetores/uso terapêutico , Administração por Inalação , Aldeídos/análise , Animais , Antioxidantes/administração & dosagem , Aquaporina 4/biossíntese , Aquaporina 4/genética , Dano Encefálico Crônico/prevenção & controle , Hemorragia Cerebral/sangue , Hemorragia Cerebral/etiologia , Progressão da Doença , Avaliação Pré-Clínica de Medicamentos , Proteínas da Matriz Extracelular/análise , Glucose/toxicidade , Hidrogênio/administração & dosagem , Hiperglicemia/induzido quimicamente , Infarto da Artéria Cerebral Média/sangue , Infarto da Artéria Cerebral Média/complicações , Masculino , Metaloproteinase 2 da Matriz/análise , Metaloproteinase 9 da Matriz/análise , Fármacos Neuroprotetores/administração & dosagem , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Tirosina/análogos & derivados , Tirosina/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA